Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk (scientific article published on 6 August 2015)

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

Q36921892

HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction

Q37733566

Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure

Q38214140

Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy

Q38376859

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

Q39433797

Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).

Q40530895

High-density lipoprotein restores endothelial function in hypercholesterolemic men.

Q43933064

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

Q44585429

Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice

Q44995472

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

Q46610834

Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2.

Q46913872

Carbamylated low-density lipoprotein induces endothelial dysfunction

Q46915576

High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality

Q57191836

P433

issue

P304

page(s)

3007-3016

P577

publication date

2015-08-06

P1433

published in

European Heart Journal

Q2286839

P1476

title

Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk

P478

volume

Reverse relations

cites work (P2860)

Q51345951	A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.
Q64105618	Altered proteome of high-density lipoproteins from paediatric acute lymphoblastic leukemia survivors
Q99629134	Angiogenic and Antiangiogenic mechanisms of high density lipoprotein from healthy subjects and coronary artery diseases patients
Q64103461	Association Between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW-CKD
Q49960373	Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.
Q92671715	Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients
Q88779694	Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris
Q97550855	Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection
Q37251396	Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients
Q90666652	Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies
Q64069819	Dysfunctional high-density lipoprotein activates toll-like receptors via serum amyloid A in vascular smooth muscle cells
Q92317291	Elevated high-density lipoprotein in adolescents with Type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation
Q42874127	Further evidence that high-density lipoprotein is a chameleon-like lipoprotein
Q101403168	HDL cholesterol efflux capacity is inversely associated with subclinical cardiovascular risk markers in young adults: The cardiovascular risk in Young Finns study
Q38739884	HDL cholesterol: reappraisal of its clinical relevance
Q64245247	High-Density Lipoprotein Function and Dysfunction in Health and Disease
Q64250648	High-Density Lipoprotein from Chronic Kidney Disease Patients Modulates Polymorphonuclear Leukocytes
Q52374541	High-Density Lipoprotein in Chronic Kidney Diseases-The Devil Is in the Detail.
Q92522355	Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation
Q38603671	Innate immunity in CKD-associated vascular diseases.
Q39293001	Lipid testing in infectious diseases: possible role in diagnosis and prognosis
Q41231925	Liver disease alters high-density lipoprotein composition, metabolism and function
Q53698735	No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases.
Q49554117	Pharmacological Intervention to Modulate HDL: What Do We Target?
Q36406335	Protective effect of HDL on NADPH oxidase-derived super oxide anion mediates hypoxia-induced cardiomyocyte apoptosis.
Q55437430	Protein markers of dysfunctional HDL in scavenger receptor class B type I deficient mice.
Q50154700	Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
Q62640193	Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation
Q91763390	Serum amyloid a protein as a potential biomarker in predicting acute onset and association with in-hospital death in acute aortic dissection
Q91917022	Structure-function relationships of HDL in diabetes and coronary heart disease
Q63684350	The effect of chronic kidney disease on lipid metabolism
Q40486461	Vegetated land cover near residence is associated with reduced allostatic load and improved biomarkers of neuroendocrine, metabolic and immune functions
Q52813315	[Clinical importance of HDL cholesterol].
Q64253258	gene polymorphisms in osteoporosis patients

P356	DOI	10.1093/EURHEARTJ/EHV352
P698	PubMed publication ID	26248570